Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Gerber, David E. [1 ]
Skelton, Rachael [1 ]
Dong, Ying [1 ]
Loudat, Laurin [1 ]
Dowell, Jonathan [1 ]
Boothman, David A. [1 ]
Sarode, Venetia [1 ]
Zhang, Wei [1 ]
Xie, Yang [1 ]
Gazdar, Adi [1 ]
Frenkel, Eugene P. [1 ]
Schiller, Joan H. [1 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Harold C Simmons Canc Ctr, Dallas, TX 75390 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8088
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Priming of non-small cell lung cancer (NSCLC) cell lines to erlotinib by the histone deacetylase (HDAC) inhibitor panobinostat
    Greve, G.
    Schiffmann, I.
    Luebbert, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 67 - 67
  • [2] Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
    Gerber, David E.
    Boothman, David A.
    Fattah, Farjana J.
    Dong, Ying
    Zhu, Hong
    Skelton, Rachel A.
    Priddy, Laurin L.
    Vo, Peggy
    Dowell, Jonathan E.
    Sarode, Venetia
    Leff, Richard
    Meek, Claudia
    Xie, Yang
    Schiller, Joan H.
    [J]. LUNG CANCER, 2015, 90 (03) : 534 - 541
  • [3] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
  • [4] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Leighl, N. B.
    Soria, J.
    Bennouna, J.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [6] Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines
    Zhang, Wei
    Peyton, Michael
    Xie, Yang
    Soh, Junichi
    Minna, John D.
    Gazdar, Adi F.
    Frenkel, Eugene P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 161 - 166
  • [7] Phase II pharmacodynamic trial of erlotinib in previously treated patients with advanced non-small-cell lung cancer (NSCLC):: Study results
    Felip, Enriqueta
    Rojo, Frederico
    Reck, Martin
    Heller, Astrid
    Klughammer, Barbara
    Maacke, Heiko
    Mocks, Joachim
    Brennscheidt, Ulrich
    Gatzemeier, Ulrich
    Baselga, Jose
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [8] Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241+nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).
    Awad, Mark M.
    Le Bruchec, Yvan
    Lu, Brian
    Miller, Julieann
    Dumitru, Calin Dan
    Spira, Alexander I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Felip, E
    Rojo, F
    Heller, A
    Foernzler, D
    Majo, J
    Klughammer, B
    Ramos, J
    Maacke, H
    Brennscheidt, U
    Baselga, J
    [J]. LUNG CANCER, 2005, 49 : S369 - S369
  • [10] Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC)
    Lynch, T. J.
    Fenton, D. W.
    Hirsh, V.
    Bodkin, D. J.
    Middleman, E.
    Chiappori, A.
    Halmos, B.
    Liu, H.
    Eton, O.
    Shepherd, W. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345